Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Alterations in the kynurenine pathway of tryptophan metabolism are associated with depression in people living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma Cotinine Cutoff for Distinguishing Smokers From Nonsmokers Among Persons Living With HIV

    Research output: Contribution to journalLetterResearch

  1. Incidence and impact of parvovirus B19 infection in seronegative solid organ transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Response to Aviv et al

    Research output: Contribution to journalLetterResearchpeer-review

  3. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sarah Amele
  • Lars Peters
  • Alison Rodger
  • Jens Lundgren
  • Jϋrgen Rockstroh
  • Raimonda Matulionyte
  • Clifford Leen
  • Elzbieta Jabłonowska
  • Lars Østergaard
  • Sanjay Bhagani
  • Mario Sarcletti
  • Amanda Clarke
  • Karolin Falconer
  • Gilles Wandeler
  • Pere Domingo
  • Fernando Maltez
  • Mauro Zaccarelli
  • Nikoloz Chkhartisvili
  • Janos Szlavik
  • Christoph Stephan
  • Laurent Fonquernie
  • Inka Aho
  • Amanda Mocroft
View graph of relations

OBJECTIVES: To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe.

METHODS: All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.

RESULTS: 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir ± RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir ± RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin.

CONCLUSIONS: Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.

Original languageEnglish
JournalJournal of acquired immune deficiency syndromes (1999)
Issue number2
Pages (from-to)248-257
Number of pages10
Publication statusPublished - 1 Feb 2021

Bibliographical note

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

ID: 61064175